(lp0
S'Atyr Pharma reports 4Q loss Yahoo Finance - Mar 16, 2017 SAN DIEGO  _ Atyr Pharma Inc.  on Thursday reported a loss of $12.6 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 53 cents.How has aTyr Pharma, Inc. performed recently? - The Daily LeicesterBasic Consolidated EPS Of aTyr Pharma Inc  At $-3.029 - Equities Focus'
p1
aS'aTyr Pharma  Receives US Patent Extending Protection of Physiocrines ... StreetInsider.com - Mar 15, 2017 aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the issuance of US Patent Number 9,428,743, which represents&nbsp;...'
p2
aS"aTyr Pharma to Present at Cowen and Company 37th Annual Health Care Conference PR Newswire  - Mar 1, 2017 SAN DIEGO, March 1, 2017 /PRNewswire/ -- aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's&nbsp;...Active Volume Stock: aTyr Pharma Inc.  - HugoPressAnalytical Review of aTyr Pharma Inc.  - The Oracle Examiner"
p3
aS'aTyr Pharma Reports Promising Signals of Clinical Activity in Multiple Rare ... PR Newswire  - Dec 13, 2016 SAN DIEGO, Dec. 13, 2016 /PRNewswire/ -- aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced clinical results from&nbsp;...'
p4
aS'aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb ... PR Newswire  - Mar 3, 2017 SAN DIEGO, March 3, 2017 /PRNewswire/ -- aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that the European&nbsp;...aTyr Pharma  Receives FDA Orphan Drug Designation for Treatment of LGMD ... - StreetInsider.comBRIEF-Atyr Pharma receives EMA orphan drug designation for the treatment of ... - Reuters'
p5
aS"aTyr Pharma Presents Additional Data for Resolaris Phase 1b/2 Trial in Adult ... PR Newswire  - Oct 6, 2016 SAN DIEGO, Oct. 6, 2016 /PRNewswire/ -- aTyr Pharma, Inc. , today announced that additional clinical data from aTyr's Phase 1b/2 Trial  in adult patients with FSHD were presented at the 21st International Congress of the World Muscle&nbsp;..."
p6
aS'aTyr Pharma Announces Second Quarter 2016 Operating Results PR Newswire  - Aug 10, 2016 SAN DIEGO, Aug. 10, 2016 /PRNewswire/ -- aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced operating results for&nbsp;...'
p7
aS'aTyr Pharma Enters into $20 Million Credit Facility PR Newswire  - Nov 21, 2016 SAN DIEGO, Nov. 21, 2016 /PRNewswire/ -- aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced it has entered into a&nbsp;...'
p8
aS'aTyr Pharma Announces Encouraging Phase 1b/2 Results for Resolaris in its ... PR Newswire  - Mar 30, 2016 SAN DIEGO, March 30, 2016 /PRNewswire/ -- aTyr Pharma, Inc.  a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced results from a&nbsp;...'
p9
aS'aTyr Pharma Inc. LIFE  Wall Street Journal - Feb 12, 2011 News aTyr Pharma Inc.LIFE. Significant News Only. 03/03/17; Press Release. aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris.'
p10
a.